BridgeBio Pharma (NASDAQ:BBIO) Given New $81.00 Price Target at Oppenheimer

BridgeBio Pharma (NASDAQ:BBIO) had its price target trimmed by Oppenheimer from $83.00 to $81.00 in a report issued on Wednesday morning,Benzinga reports. The brokerage currently has an outperform rating on the stock.

Other research analysts also recently issued research reports about the stock. JPMorgan Chase & Co. boosted their target price on shares of BridgeBio Pharma from $76.00 to $77.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of BridgeBio Pharma in a research report on Wednesday, January 21st. Piper Sandler upped their price objective on shares of BridgeBio Pharma from $93.00 to $98.00 and gave the company an “overweight” rating in a research note on Thursday, October 30th. Leerink Partners lifted their target price on shares of BridgeBio Pharma from $75.00 to $86.00 and gave the stock an “outperform” rating in a research note on Monday, December 15th. Finally, Barclays assumed coverage on BridgeBio Pharma in a research note on Wednesday, January 28th. They set an “overweight” rating on the stock. Twenty-two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $82.50.

BridgeBio Pharma Price Performance

Shares of BBIO opened at $66.54 on Wednesday. BridgeBio Pharma has a 1-year low of $28.33 and a 1-year high of $84.94. The stock has a market cap of $12.82 billion, a price-to-earnings ratio of -17.60 and a beta of 1.13. The firm has a 50 day simple moving average of $75.09 and a 200-day simple moving average of $64.54.

BridgeBio Pharma (NASDAQ:BBIO) last announced its earnings results on Tuesday, February 24th. The company reported ($1.00) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.25). The business had revenue of $154.18 million during the quarter, compared to analysts’ expectations of $150.71 million. During the same quarter in the previous year, the business posted ($1.40) EPS. The business’s revenue was up 2521.2% compared to the same quarter last year. On average, equities analysts expect that BridgeBio Pharma will post -3.67 earnings per share for the current fiscal year.

Insider Activity at BridgeBio Pharma

In other BridgeBio Pharma news, CFO Thomas Trimarchi sold 13,600 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $74.72, for a total transaction of $1,016,192.00. Following the completion of the sale, the chief financial officer owned 336,585 shares of the company’s stock, valued at approximately $25,149,631.20. The trade was a 3.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Neil Kumar sold 28,053 shares of the company’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $71.39, for a total value of $2,002,703.67. Following the sale, the chief executive officer owned 234,451 shares of the company’s stock, valued at $16,737,456.89. This represents a 10.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 204,174 shares of company stock valued at $15,012,335 over the last quarter. 18.20% of the stock is currently owned by corporate insiders.

Institutional Trading of BridgeBio Pharma

A number of institutional investors have recently modified their holdings of the company. Invesco Ltd. increased its position in BridgeBio Pharma by 23.0% during the 4th quarter. Invesco Ltd. now owns 4,831,305 shares of the company’s stock worth $369,547,000 after purchasing an additional 902,648 shares in the last quarter. Mackenzie Financial Corp grew its stake in BridgeBio Pharma by 8.9% during the fourth quarter. Mackenzie Financial Corp now owns 54,495 shares of the company’s stock worth $4,105,000 after buying an additional 4,448 shares during the period. XTX Topco Ltd increased its position in shares of BridgeBio Pharma by 162.4% in the fourth quarter. XTX Topco Ltd now owns 13,169 shares of the company’s stock worth $1,007,000 after acquiring an additional 8,150 shares in the last quarter. VARCOV Co. purchased a new position in shares of BridgeBio Pharma in the 4th quarter valued at $340,000. Finally, Voloridge Investment Management LLC raised its stake in shares of BridgeBio Pharma by 377.4% in the 4th quarter. Voloridge Investment Management LLC now owns 638,883 shares of the company’s stock valued at $48,868,000 after acquiring an additional 505,051 shares during the period. Hedge funds and other institutional investors own 99.85% of the company’s stock.

BridgeBio Pharma News Roundup

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Q4 revenue beat and commercial update — BridgeBio reported $154.2M in Q4 revenue (well above estimates) and provided commercial progress on Attruby, which supports the company’s path to commercialization and helped lift sentiment. BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates
• Positive Sentiment: Multiple analyst price-target increases — Morgan Stanley, Truist and other firms raised targets (Morgan Stanley to $98, Truist to $95 and others higher), signaling continued analyst confidence and providing upside thesis for longer-term holders. Analyst Coverage
• Neutral Sentiment: Conference call / transcripts available — The full earnings call and transcripts are published for investors to parse forward guidance and commercial cadence; further detail could move the stock once digested. Listen to Conference Call
• Neutral Sentiment: Short-interest report appears irregular — the February short-interest entry shows 0 shares / NaN change, likely a reporting glitch; this makes short-interest an unreliable read today. (No reliable source link provided in the alert.)
• Negative Sentiment: EPS missed expectations — BridgeBio reported a $1.00 loss per share vs. the consensus -$0.75, a larger-than-expected loss that is pressuring the stock despite the revenue beat. Zacks: Q4 Loss, Beats Revenue Estimates
• Negative Sentiment: Insider selling by CEO — CEO Neil Kumar sold ~28k shares (part of a pattern of recent sales), which can be interpreted negatively by some investors as liquidity-taking by management. InsiderTrades: Neil Kumar Sells Shares
• Negative Sentiment: One analyst trimmed target slightly — Oppenheimer lowered its target to $81 (still an outperform), introducing a modest counterpoint to the otherwise bullish analyst activity. Benzinga: Oppenheimer Price Target Change

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.